And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to escort Mrs. Pharmalot to a rent party, catch up on our growing pile of books, and promenade with our official mascot. And what about you? This is a fine time to catch up with someone special, whittle down your own reading list, do some binge-watching, or you could plan a spring season getaway. Or maybe you want to store provisions in the event of another U.S. government shutdown. Well, whatever you do, have a grand time. but be safe. Enjoy, and see you soon …

The Trump administration has been trumpeting a huge increase in generic drug approvals the past two years, but nearly half of those newly approved medicines are not being sold in the U.S., Kaiser Health News reveals. More than 700, or about 43 percent, of the generics were not on the market as of early January. Notably, 36 percent of the generics that would be the first to compete against a branded drug are not yet for sale. “It’s a real problem because we’re not getting all the expected competition,” says FDA Commissioner Scott Gottlieb.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy